ClinicalTrials.gg
RecruitingNCT04669717AMAUpdated Apr 29, 2026

Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies

A Phase 4 interventional study of 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days and 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days in Periodontal Diseases, Antibiotics and Pharmacokinetics, sponsored by University of Geneva, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by University of Geneva, Switzerland · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Periodontitits is a bacteria induced inflammatory disease that destroys the supporting tissues of the tooth and leads to tooth loss. Treatment consists mainly of the mechanical cleaning of the tooth surfaces in order to remove the bacterial deposits (plaque and calculus). This procedure can reduce the level of pathogenic bacteria but it can not eradicate them. In severe cases, for the complete resolution of the disease, the elimantion of certain species of bacteria is needed. In order to achieve that, the combination of different regimens of antibiotics adjunctive to the mechanical treatment has been proposed. However, dosage and duration of antimicrobial therapy should be optimal and not excessive as issues may arise related to increased antimicrobial resistance in the population and the individual due to habitual prescription of wide-spectrum antibiotic regimens, horizontal gene transfer and genetic mutation.

In the present study, in an effort to optimize the dosage and duration of the antimicrobial regimen, we will determine the pharmacokinetics (PK) and pharmacodynamic (PD) properties of the MET-AMO combination and of AZI in Gingival Crevicular Fluid (GCF), saliva and serum in severe periodontitis patients during and after either a 3-day or a 7-day course of treatment.

Read the detailed description

This is a randomized, 3-arm parallel group, single-blind, comparative superiority and exploratory clinical trial of 44 months involving 45 patients with periodontitis attending the Division of Regenarative Dental Medecine and Periodontology of the University of Geneva. First, a routine clinical and radiographic periodontal examination will be conducted by a periodontist. Treatment will be done in 2 appointments by mechanical debridement of the diseased sites by two experienced clinicians. At the end of the treatment, one third of the patients will be assigned for treatment with 500mgAMO+ 500mgMET 3 times a day during 1 week, one third for treatment with 500mgAMO+ 500mgMET 3 times a day during 3 days and the last third for treatment with 500mg AZI once a day for 3 days.

Clinical samples will be taken at Days 0, 2, 4 and 8 after the start of the antibiotic administration . Gingival Crevicular Fluid (GCF) will be collected from four sites with paperpoints, blood sample by finger puncture, unstimulated saliva and subgingival plaque from four sites with paper points. The concentration and duration effect of AMO+MET and AZI in GCF, saliva and serum will be assessed in the Laboratory of Clinical Pharmacology at the University Hospital of Lausanne (CHUV) by high performance liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The microbiological effect on 6 selected organisms will be assessed by RT-PCR at 3 and 6 months after treatment. The clinical results will be evaluated 6 months later. The study duration for the patient will be approximately 8 months.

All adverse events (AE) and all serious adverse events (SAEs) will be recorded and addressed.

02

Conditions studied

  • Periodontal Diseases
  • Antibiotics
  • Pharmacokinetics

Browse trials for

03

In context

Periodontal Diseases

871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.

This study's planned enrollment of 45 is close to the median of 45 across 559 interventional studies indexed under Periodontal Diseases.

Browse Periodontal Diseases studies →

Lead sponsor

University of Geneva, Switzerland is the lead sponsor of 43 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature
  • Aged 18-80 years old with need of periodontal treatment associated with adjunctive antibiotic therapy
  • Presence of at least 30% of the teeth in the mouth with PD>6mm and BOP

Exclusion criteria

Exclusion Criteria:

  • Persons with systemic illnesses (uncontrolled diabetes mellitus, cancer, , bone metabolic diseases or disorders that compromise wound healing, radiation, or therapy)
  • Pregnancy or lactation
  • Persons who had taken AB within the previous 2 months
  • Persons who are taking nonsteroidal anti-inflammatory drugs
  • Persons who have a confirmed or suspected intolerance to 5-nitroimidazole derivatives or amoxicillin or macrolides
  • Previous periodontal therapy the last 1 year
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow due to language problems, psychological disorders, dementia, etc. of the participant
  • Participants not willing to attend regular dental maintenance visits and follow-up evaluations
  • Participation in another study with drug within the 30 days preceding and during the present study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    Amoxicilline and Metronidazole for 7 days

    Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 7 days Systemic antibiotics after sub gingival mechanical debridement

    Drug: 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days

  • Active comparator
    Amoxicilline and Metronidazole for 3 days

    Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 3 days Systemic antibiotics after sub gingival mechanical debridement

    Drug: 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days

  • Active comparator
    Azithromycine for 3 days

    Drug: AZITHROMYCIN Pfizer cpr pell 500mg, Pfizer PFE Switzerland GmbH 1/d 500mg for 3 days Systemic antibiotics after sub gingival mechanical debridement

    Drug: 1/d 500 mg Azithromycine Pfizer for 3 days

Interventions

  • Drug3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days

    Non-surgical periodontal therapy and radnomly administration of the antibiotics

    Also known as: AMOXICILLINE Sandoz cpr pell 500 mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500 mg, Sanofi-Aventis ( Suisse) SA

  • Drug3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days

    Non-surgical periodontal therapy and radnomly administration of the antibiotics

    Also known as: AMOXICILLINE Sandoz cpr pell 500 mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500 mg, Sanofi-Aventis ( Suisse) SA

  • Drug1/d 500 mg Azithromycine Pfizer for 3 days

    Non-surgical periodontal therapy and radnomly administration of the antibiotics

    Also known as: AZITHROMYCIN Pfizer cpr pell 500mg, Pfizer PFE Switzerland GmbH

06

What researchers measure

Primary outcomes

  1. The concentration of AMO+MET and AZI in GCF, saliva and serum

    The concentration of the drugs will be assessed in samples of gingival crevicular fluid, saliva and serum at days 0, 2, 4 and 8 after the start of the antibiotic administration.The concentration of the studied antibiotics in the different fluids will be expressed as ng/ml

    Time frame: At Day 0,2,4,8 post-dose

Secondary outcomes

  1. Differences between the three treatment arms in the proportion of participants classed as treatment success at 6 months; defined as absence of sites with PD ≥ 5 mm and concomitant bleeding on probing.

    Comparisons between groups assessed at 3 and 6 months after treatment

    Time frame: At Month 3 and Month 6 post-intervention

  2. Differences between the three treatment arms in the levels of 6 organisms in subgingival plaque samples. For those bacteria with a threshold of >1000cells/ml, results will be expressed as median counts.

    Comparisons between groups will be assessed at 3 and 6 months after treatment

    Time frame: At Month 3 and Month 6 post-intervention

  3. Number of participant per treatment arm with adverse events as a mesure of safety.

    Adverse events will be collected from the start of study treatment and until the end of the study (at 6 months evaluation)

    Time frame: At Day 2, Day 4 and Day 8 post-intervention

  4. Patient's compliance will be evaluated

    Compliance will be evaluated by pill count at the end of the antibiotherapy.

    Time frame: At Day 8 after intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Giannopoulou C, Cionca N, Almaghlouth A, Cancela J, Courvoisier DS, Mombelli A. Systemic Biomarkers in 2-Phase Antibiotic Periodontal Treatment: A Randomized Clinical Trial. J Dent Res. 2016 Mar;95(3):349-55. doi: 10.1177/0022034515618949. Epub 2015 Nov 24. PubMed 26604272 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2028, 87 months after the start.

Of 24 phase 4 interventional studies under Periodontal Diseases, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 87 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2020
First posted
Dec 17, 2020
StartActual
Sep 1, 2021
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04669717
Lead sponsor
University of Geneva, Switzerland
Collaborators
University of Lausanne
Responsible party
Catherine Giannopoulou (Professor, University of Geneva, Switzerland) — Principal investigator
First posted
Dec 17, 2020
Start date
Sep 1, 2021
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Catherine Giannopoulou, Dr med dent
Contact
ekaterini.giannopoulou@unige.ch
0041223794068
Alkisti Zekeridou, Dr med dent
Contact
alkisti.zekeridou@unige.ch
0041223794031
Catherine Giannopoulou, Dr med dent
principal investigator · University Clinics of Dental Medicine, University of Geneva

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion